Table 3 Pre- and postprocedural regimens, partial or full recapture of the device, resizing of the device

Chen et al. (2019) [21]

N/A

VKA: n = 13 / 56.7%;

NOAC: n = 17 / 1.7%

OAC: n = 1 / 3.3%

DAPT for 6 months, followed by lifetime ASS: n = 29 / 96.7%

14 / 46.7%

N/A

0

Feng et al. (2019) [22]

Brockenbrough needle and SL1 transseptal sheath (St. Jude Medical)

N/A

DAPT for 3 months, followed by lifetime ASS

N/A

N/A

1 / 5.9%

Reinsch et al. (2018) [19]

Brockenbrough needle and SL1 transseptal sheath (St. Jude Medical)

N/A

DAPT for 6 months, followed by lifetime ASS

11 / 27%

1 / 9%

1 / 9%

Park et al. (2018) [18]

N/A

ASS: n = 46 / 78%;

Clopidogrel: n = 49 / 82%;

heparin: n = 14 / 23%;

VKA: n = 2 / 3.3%;

NOAC: n = 1 / 1.7%

DAPT for 3 months

21 / 38%

9 / 14%

3 / 5%

Kleinecke et al. (2018) [17]

Brockenbrough needle (St. Jude Medical)

N/A

N/A

N/A

20 / 100%

0

Cruz-Gonzalez et al. (2018) [20]

N/A

N/A

DAPT: n = 3 / 43%

SAPT: n = 1 / 14%

NOAC: n = 2 / 28%

LMWH: n = 1 / 14%

N/A

N/A

N/A

Chen et al. (2018) [9]

N/A

N/A

DAPT: n = 29 / 96.7%

N/A

1 / 3.3%

N/A

Zhou et al. (2017) [16]

N/A

VKA: n = 21 / 100%

N/A

N/A

N/A

N/A

Huang et al. (2017) [15]

N/A

N/A

N/A

N/A

N/A

N/A

Jie et al. (2016) [14]

Brockenbrough needle with SL1 transseptal sheath (St. Jude Medical)

ASS: n = 13 / 18%

Clopidogrel: n = 5 / 7%

VKA: n = 18 / 25%

N/A

N/A

N/A

N/A

Total /

Overall mean

Brockenbrough needle, mostly used with the SL1 transseptal sheath

VKA or NOAC:

n = 72/165 = 43.6%

Other:

n = 93/165 = 56.4%

DAPT in

n = 150/155 = 96.8%

46 / 45.5%

31 / 25.6%

5 / 3.6%